Skip to main content
Journal cover image

ACR Appropriateness Criteria® Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: 2022 Update.

Publication ,  Journal Article
Expert Panel on Urological Imaging, ; Akin, O; Woo, S; Oto, A; Allen, BC; Avery, R; Barker, SJ; Gerena, M; Halpern, DJ; Gettle, LM; Taneja, SS ...
Published in: J Am Coll Radiol
May 2023

Prostate cancer is second leading cause of death from malignancy after lung cancer in American men. The primary goal during pretreatment evaluation of prostate cancer is disease detection, localization, establishing disease extent (both local and distant), and evaluating aggressiveness, which are the driving factors of patient outcomes such as recurrence and survival. Prostate cancer is typically diagnosed after the recognizing elevated serum prostate-specific antigen level or abnormal digital rectal examination. Tissue diagnosis is obtained by transrectal ultrasound-guided biopsy or MRI-targeted biopsy, commonly with multiparametric MRI without or with intravenous contrast, which has recently been established as standard of care for detecting, localizing, and assessing local extent of prostate cancer. Although bone scintigraphy and CT are still typically used to detect bone and nodal metastases in patients with intermediate- or high-risk prostate cancer, novel advanced imaging modalities including prostatespecific membrane antigen PET/CT and whole-body MRI are being more frequently utilized for this purpose with improved detection rates. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Coll Radiol

DOI

EISSN

1558-349X

Publication Date

May 2023

Volume

20

Issue

5S

Start / End Page

S187 / S210

Location

United States

Related Subject Headings

  • United States
  • Ultrasonography
  • Societies, Medical
  • Prostatic Neoplasms
  • Positron Emission Tomography Computed Tomography
  • Nuclear Medicine & Medical Imaging
  • Neoplasm Staging
  • Male
  • Magnetic Resonance Imaging
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Expert Panel on Urological Imaging, ., Akin, O., Woo, S., Oto, A., Allen, B. C., Avery, R., … Nikolaidis, P. (2023). ACR Appropriateness Criteria® Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: 2022 Update. J Am Coll Radiol, 20(5S), S187–S210. https://doi.org/10.1016/j.jacr.2023.02.010
Expert Panel on Urological Imaging, Paul, Oguz Akin, Sungmin Woo, Aytekin Oto, Brian C. Allen, Ryan Avery, Samantha J. Barker, et al. “ACR Appropriateness Criteria® Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: 2022 Update.J Am Coll Radiol 20, no. 5S (May 2023): S187–210. https://doi.org/10.1016/j.jacr.2023.02.010.
Expert Panel on Urological Imaging, Akin O, Woo S, Oto A, Allen BC, Avery R, et al. ACR Appropriateness Criteria® Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: 2022 Update. J Am Coll Radiol. 2023 May;20(5S):S187–210.
Expert Panel on Urological Imaging, Paul, et al. “ACR Appropriateness Criteria® Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: 2022 Update.J Am Coll Radiol, vol. 20, no. 5S, May 2023, pp. S187–210. Pubmed, doi:10.1016/j.jacr.2023.02.010.
Expert Panel on Urological Imaging, Akin O, Woo S, Oto A, Allen BC, Avery R, Barker SJ, Gerena M, Halpern DJ, Gettle LM, Rosenthal SA, Taneja SS, Turkbey B, Whitworth P, Nikolaidis P. ACR Appropriateness Criteria® Pretreatment Detection, Surveillance, and Staging of Prostate Cancer: 2022 Update. J Am Coll Radiol. 2023 May;20(5S):S187–S210.
Journal cover image

Published In

J Am Coll Radiol

DOI

EISSN

1558-349X

Publication Date

May 2023

Volume

20

Issue

5S

Start / End Page

S187 / S210

Location

United States

Related Subject Headings

  • United States
  • Ultrasonography
  • Societies, Medical
  • Prostatic Neoplasms
  • Positron Emission Tomography Computed Tomography
  • Nuclear Medicine & Medical Imaging
  • Neoplasm Staging
  • Male
  • Magnetic Resonance Imaging
  • Humans